CAR T-cell Therapy is one of the most advanced forms of immunotherapy used to treat certain types of cancer, especially blood cancers such as leukemia, lymphoma, and multiple myeloma. This therapy works by modifying a patient’s own immune cells (T cells) in a laboratory so they can recognize and attack cancer cells more effectively. Once engineered, these cells are infused back into the patient to target and destroy tumors.

Interest in this innovative treatment continues to rise. A study by Grand View Research indicates that CAR T-cell Therapy market is expected to grow at a CAGR of 18.06% from 2026 to 2033, driven by increasing clinical research, technological advances in cell engineering, and expanding applications in oncology.

What is CAR T-cell Therapy?

CAR T-cell Therapy stands for Chimeric Antigen Receptor T-cell therapy. It involves collecting a patient’s T cells, genetically modifying them to express special receptors that recognize cancer cells, and then reinfusing them into the body to attack the disease.

Key steps in the treatment process include:

1. T-cell collection from the patient’s blood

2. Genetic modification of the cells in a laboratory

3. Expansion of engineered cells to large numbers

4. Reinfusion into the patient to destroy cancer cells

This approach has shown remarkable success in patients whose cancers did not respond to conventional therapies such as chemotherapy or radiation.

CAR T-cell Therapy Companies

Several biotechnology and pharmaceutical companies are leading the development of CAR T-cell therapies worldwide.

Major CAR T-cell therapy companies

• Novartis: Developed Kymriah, one of the first approved CAR T-cell therapies for leukemia and lymphoma.

• Gilead Sciences (Kite Pharma): Developed Yescarta and continues to expand research through acquisitions and partnerships in cell therapy technologies. 

• Bristol Myers Squibb: Developed therapies such as Abecma for multiple myeloma.

• Johnson & Johnson (Legend Biotech partnership): Developed Carvykti, another CAR-T therapy for multiple myeloma.

• ImmunoACT (India): A Mumbai-based biotechnology company developing indigenous CAR-T therapies such as NexCAR19, helping reduce treatment costs.

These companies continue to invest heavily in research to expand CAR-T therapy applications beyond blood cancers to solid tumors and autoimmune diseases.

Latest Trends in CAR T-cell Therapy

The CAR T-cell therapy field is evolving rapidly with new innovations and research breakthroughs.

In-Vivo CAR T-cell Engineering: Scientists are developing methods to engineer CAR-T cells directly inside the body, eliminating the need for complex laboratory manufacturing. Pharmaceutical companies are investing heavily in this technology. 

Dual-Target CAR-T Cells: New therapies are being designed to target multiple cancer markers simultaneously, improving treatment effectiveness and reducing relapse risk.

AI-Driven Drug Discovery: Artificial intelligence is being used to identify new cancer targets, design CAR constructs, and accelerate therapy development.

Expansion Beyond Blood Cancers: Researchers are exploring CAR-T therapies for solid tumors such as brain cancer, lung cancer, and pancreatic cancer.

Benefits of CAR T-cell Therapy

CAR T-cell therapy offers several advantages compared with conventional cancer treatments.

Key benefits include:

• Personalized treatment using the patient’s own immune cells

• High response rates in certain blood cancers

• Potential long-term remission in resistant cancers

• Targeted destruction of cancer cells with minimal damage to healthy tissue

Although side effects can occur, advances in treatment protocols and monitoring have significantly improved patient safety.

Future Outlook

CAR T-cell therapy is widely considered one of the most promising breakthroughs in modern oncology. Ongoing research is focused on improving accessibility, reducing treatment costs, and expanding therapy indications to more cancer types.

With continued investment from biotechnology companies, academic institutions, and healthcare organizations, CAR T-cell therapy is expected to become a cornerstone of precision cancer treatment in the coming years.